Dr. Agarwal's Healthcare Posts Strong Q3 Growth, Eyes Ethiopia Expansion

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Dr. Agarwal's Healthcare Posts Strong Q3 Growth, Eyes Ethiopia Expansion
Overview

Dr. Agarwal's Healthcare Limited reported a robust Q3 FY2026 with 21.8% YoY total income growth to ₹540 Cr and a 54.5% PAT surge to ₹44 Cr. Nine-month figures also showed strong double-digit growth. The company expanded its network to 272 facilities and announced plans for a wholly-owned subsidiary in Ethiopia, signaling international ambitions.

📉 The Financial Deep Dive

Dr. Agarwal's Healthcare Limited announced a strong financial performance for Q3 FY2026, reporting Total Income of ₹540 Crores, a substantial 21.8% increase year-on-year (YoY). Revenue from Operations grew by 23.0% YoY to ₹530 Crores. The company demonstrated improved profitability with EBITDA reaching ₹155 Crores, up 21.3% YoY. Profit After Tax (PAT) saw a significant jump of 54.5% YoY to ₹44 Crores.

For the nine months ended December 31, 2025 (9M FY2026), the financial trajectory remained robust. Total Income climbed to ₹1,548 Crores, marking 20.8% YoY growth. Revenue from Operations increased by 21.2% YoY to ₹1,516 Crores. EBITDA for the nine-month period grew 23.6% YoY to ₹440 Crores, while PAT recorded an impressive 74.3% YoY growth to ₹118 Crores.

🏥 Operational Expansion

The company's operational network expanded to 272 facilities as of December 31, 2025. During Q3 FY2026, 14 new centers were added, and 38 new centers were added during the nine-month period, reflecting aggressive organic growth.

🌍 Strategic Initiatives

In a significant move, the Board of Directors approved the incorporation of a wholly-owned subsidiary in Ethiopia, through its Mauritius subsidiary, Orbit Healthcare Services (Mauritius) Limited. This entity will focus on comprehensive eye care services. The company also announced the shifting of its registered and corporate office within Chennai.

Furthermore, the Shareholders Agreement concerning Idearx Services Private Limited ('Idearx') will be amended, leading to Idearx ceasing to be an 'Associate' to Dr. Agarwal's Health Care Limited, though the company will retain its 14.54% equity stake.

📈 Management Outlook

Management expressed confidence in meeting its annual guidance, citing resilient demand and strong momentum in expansion plans. The outlook is focused on accelerating organic growth through aggressive greenfield expansion and deepening its presence in existing markets, while selectively entering newer geographies, leveraging its brand strength and scalable platform.

🚩 Risks & Outlook

While growth is strong, key risks include the successful execution and integration of the Ethiopian subsidiary, increasing competition within the healthcare sector, and maintaining operational efficiency across an expanding network. Investors will watch the company's ability to sustain this growth momentum and profitability in new and existing markets.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.